HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD34(+) immunoselected cells for poor graft function following allogeneic BMT.

AbstractBACKGROUND:
Poor graft function without signs of graft rejection following allogeneic BMT (allo-BMT) occurs in around 9% of patients. A high incidence of hazardous complications may be encountered, leading to life-threatening situations.
METHODS:
We describe three patients who underwent allo-BMT for acute leukemia in first complete remission and untreated myelodysplastic syndrome. The three patients experienced prolonged and profound granulocytopenia, anemia and thrombocytopenia, despite growth factors and transfusions. This was not corrected by donor leukocytes infusion. They received a boost of CD34(+) positively-selected cells from their HLA-identical sibling donors.
RESULTS:
A rapid improvement of peripheral blood cell counts was observed in both patients who were in full donor chimerism status at time of boost infusion, whereas the patient with mixed chimerism did not show any signs of improvement. Neither patient suffered further exacerbation of GvHD.
DISCUSSION:
Allogeneic positively-immunoselected CD34(+) cells can represent an interesting alternative treatment for poor graft function following allo-BMT, in the absence of graft rejection signs.
AuthorsM Mohty, C Faucher, C Chabannon, N Vey, A M Stoppa, P Ladaique, G Novakovitch, S Olivero, R Bouabdallah, J A Gastaut, D Maraninchi, D Blaise
JournalCytotherapy (Cytotherapy) Vol. 2 Issue 5 Pg. 367-70 ( 2000) ISSN: 1465-3249 [Print] England
PMID12044228 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antigens, CD34
  • Histocompatibility Antigens
  • Immunosuppressive Agents
Topics
  • Adult
  • Antigens, CD34 (analysis, immunology, therapeutic use)
  • Blood Cells (chemistry, transplantation)
  • Blood Donors
  • Bone Marrow Transplantation (adverse effects, immunology)
  • Cell- and Tissue-Based Therapy (methods)
  • Graft Rejection
  • Histocompatibility Antigens (immunology)
  • Humans
  • Immunosuppressive Agents (pharmacology)
  • Immunotherapy (methods)
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (immunology, therapy)
  • Siblings
  • Transplantation Chimera
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: